Ads
related to: mercksiemens.com has been visited by 10K+ users in the past month
Search results
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 18 hours agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 23 hours agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday, Benzinga reports ...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 14 hours agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Merck Supports PAH Patients With Unbranded Campaign -- And New Drug
MediaPost· 5 hours agoPatients can “Outnumber PAH” by developing a strong support team, advises an unbranded educational campaign launched by Merck against pulmonary arterial hypertension (PAH) ...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 4 days agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients
FOX 23 News Albany· 21 hours agoHuma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGaA,...
On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23
FierceBiotech· 16 hours agoFive months ago, Merck revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar ...
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks via Yahoo Finance· 5 days agoAlthough the revenue and EPS for Merck (MRK) give a sense of how its business performed in the...
Merck stock gains on Q1 2024 beat (NYSE:MRK)
Seeking Alpha· 5 days agoMerck (MRK) stock gains as the company posts better than expected Q1 2024 financials with strong sales growth from its cancer medicine Keytruda. Read...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Reuters via AOL· 5 days ago(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecast on the back of...
